These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 20406071

  • 21. Malignant biliary obstruction: value of imaging findings.
    Stroszczynski C, Hunerbein M.
    Abdom Imaging; 2005; 30(3):314-23. PubMed ID: 15965779
    [Abstract] [Full Text] [Related]

  • 22. Liquid chromatography/nuclear magnetic resonance spectroscopy and liquid chromatography/mass spectrometry identification of novel metabolites of the multidrug resistance modulator LY335979 in rat bile and human liver microsomal incubations.
    Ehlhardt WJ, Woodland JM, Baughman TM, Vandenbranden M, Wrighton SA, Kroin JS, Norman BH, Maple SR.
    Drug Metab Dispos; 1998 Jan; 26(1):42-51. PubMed ID: 9443851
    [Abstract] [Full Text] [Related]

  • 23. [Urinary free L-fucose (UFC) and urinary sulfated bile acids (U-SBA)].
    Mashige F.
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():774-8. PubMed ID: 16149638
    [No Abstract] [Full Text] [Related]

  • 24. [Ultrasonic percutaneous imaging of neoplasms of liver, biliary tract and pancreas].
    Tsuchiya Y, Nakano T, Tsunetomi S, Shinagawa T, Ukazi H, Unozawa T, Iino Y, Watanabe J, Morita M, Kimura K, Saisyo H, Ohto M, Ebara M, Karasawa E, Saotome N.
    Nihon Rinsho; 1982 Aug; 40(1):102-8. PubMed ID: 6283196
    [No Abstract] [Full Text] [Related]

  • 25. Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy.
    Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttilä I, Alhava E.
    Anticancer Res; 1995 Aug; 15(6B):2731-7. PubMed ID: 8669855
    [Abstract] [Full Text] [Related]

  • 26. [The cytological study of the bile in the diagnosis of pancreatobiliary cancer].
    Kharchenko VP, Galil-Ogly GA, Ingberman IaKh, Liutfaliev TA, Kunda MA.
    Vestn Khir Im I I Grek; 1990 Nov; 145(11):33-7. PubMed ID: 1966159
    [Abstract] [Full Text] [Related]

  • 27. Tumors of the liver, extrahepatic biliary tract, and pancreas.
    Cleary KR.
    Clin Lab Med; 1987 Mar; 7(1):57-62. PubMed ID: 3030613
    [Abstract] [Full Text] [Related]

  • 28. Cancers of the pancreas and hepatobiliary system.
    Sauerland C, Engelking C, Wickham R, Pearlstone DB.
    Semin Oncol Nurs; 2009 Feb; 25(1):76-92. PubMed ID: 19217507
    [Abstract] [Full Text] [Related]

  • 29. Targeted metabolomics for biomarker discovery.
    Griffiths WJ, Koal T, Wang Y, Kohl M, Enot DP, Deigner HP.
    Angew Chem Int Ed Engl; 2010 Jul 26; 49(32):5426-45. PubMed ID: 20629054
    [Abstract] [Full Text] [Related]

  • 30. Novel diagnostic and prognostic biomarkers in biliary tract cancer.
    Skipworth JR, Timms JF, Pereira SP.
    Expert Opin Med Diagn; 2013 Sep 26; 7(5):487-99. PubMed ID: 23971898
    [Abstract] [Full Text] [Related]

  • 31. Proteomic approaches in lung cancer biomarker development.
    Cho JY, Sung HJ.
    Expert Rev Proteomics; 2009 Feb 26; 6(1):27-42. PubMed ID: 19210125
    [Abstract] [Full Text] [Related]

  • 32. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases.
    Quinones MP, Kaddurah-Daouk R.
    Neurobiol Dis; 2009 Aug 26; 35(2):165-76. PubMed ID: 19303440
    [Abstract] [Full Text] [Related]

  • 33. [Pancreatic and biliary tract cancers].
    Sawada T, Yamada N, Hirakawa K.
    Gan To Kagaku Ryoho; 2001 Jun 26; 28(6):865-71. PubMed ID: 11432359
    [Abstract] [Full Text] [Related]

  • 34. Metabolomic profiling of human urine in hepatocellular carcinoma patients using gas chromatography/mass spectrometry.
    Wu H, Xue R, Dong L, Liu T, Deng C, Zeng H, Shen X.
    Anal Chim Acta; 2009 Aug 19; 648(1):98-104. PubMed ID: 19616694
    [Abstract] [Full Text] [Related]

  • 35. Metabolomics in urogenital cancer.
    Bujak R, Daghir E, Rybka J, Koslinski P, Markuszewski MJ.
    Bioanalysis; 2011 Apr 19; 3(8):913-23. PubMed ID: 21510764
    [Abstract] [Full Text] [Related]

  • 36. [Urine diacetylspermine as a novel tumor marker].
    Yamaguchi K, Kaku T, Enjoji M, Kato M, Anai M, Kawakita M, Hamasaki N, Tanaka M.
    Rinsho Byori; 2005 Feb 19; 53(2):130-5. PubMed ID: 15796046
    [Abstract] [Full Text] [Related]

  • 37. [Tumor markers for pancreatic and biliary tract cancer].
    Takezako Y, Okusaka T, Ueno H, Ikeda M, Morizane C, Najima M.
    Gan To Kagaku Ryoho; 2004 Sep 19; 31(9):1443-6. PubMed ID: 15446574
    [Abstract] [Full Text] [Related]

  • 38. High mobility group A1 is expressed in metastatic adenocarcinoma to the liver and intrahepatic cholangiocarcinoma, but not in hepatocellular carcinoma: its potential use in the diagnosis of liver neoplasms.
    Abe N, Watanabe T, Izumisato Y, Suzuki Y, Masaki T, Mori T, Sugiyama M, Fusco A, Atomi Y.
    J Gastroenterol; 2003 Sep 19; 38(12):1144-9. PubMed ID: 14714251
    [Abstract] [Full Text] [Related]

  • 39. [A survey on the diagnosis and treatment of biliary tract cancers in Shanghai].
    Wang BS, Qin J, Deng J, Zhang BH, Han TQ, Shen MC, Rashid A, Hsing AW, Gao YT.
    Zhonghua Wai Ke Za Zhi; 2005 Apr 01; 43(7):455-9. PubMed ID: 15854373
    [Abstract] [Full Text] [Related]

  • 40. [Selective deposition of agrin in the microvasculature of hepatocellular carcinoma: aspects in pathogenesis and differential diagnosis].
    Tátrai P.
    Magy Onkol; 2008 Dec 01; 52(4):379-83. PubMed ID: 19068466
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.